Olumiant (Baricitinib) for Rheumatoid Arthritis | myRAteam

Connect with others who understand.

sign up Log in
About myRAteam
Powered By

Olumiant is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. Olumiant is also referred to by its drug name, baricitinib.

Olumiant is a disease-modifying antirheumatic drug (DMARD). Olumiant is also a Janus kinase (JAK) inhibitor. Olumiant is believed to work by disrupting chemical signals involved in inflammation.

How do I take it?
Prescribing information states that Olumiant is taken orally as a tablet once daily.

Side effects
The FDA-approved label for Olumiant lists common side effects including respiratory tract infections, nausea, and herpes virus infections.

Rare but serious side effects listed for Olumiant can include severe infections, life-threatening blood clots, stomach and intestinal damage, and an increased risk of developing lymphoma or other types of cancer.

For more information, visit:

Olumiant — Lilly

Baricitinib — Arthritis Foundation

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of use and Privacy policy.
Already a Member? Log in